Selagine Plasma, Inc., announced in a press release that it has received certain intellectual property rights from Selagine, Inc. and the University of Illinois Chicago to develop pooled human plasma products and pursue related commercialization activities for ophthalmic applications, including an investigational pooled plasma eye drop program for moderate-to-severe dry eye disease and related ocular surface disorders.

Selagine Plasma is developing a patent-pending pooled plasma platform intended to transition blood-derived ocular surface therapy from individualized, patient-specific preparation toward a standardized biologic manufacturing model. The program is designed around screened donors, plasmapheresis collection, pooled plasma, closed-system manufacturing, pathogen reduction, sterile single-use dispensing, and defined release specifications, the company said in the press release.

A central design principle of Selagine Plasma's program is the development of quiescent plasma: a pooled plasma product engineered to reduce inflammatory and platelet-activation-associated mediators while retaining potentially beneficial plasma-derived components. Because moderate-to-severe dry eye is often associated with ocular surface inflammation, Selagine Plasma said it is designing the product around the ocular surface's inflammatory biology while addressing limitations of localized compounding workflows.

Selagine Plasma's pooled plasma eye drop program is investigational and has not been approved by the US Food and Drug Administration (FDA). The company said it expects to pursue an appropriate FDA development pathway before any commercial launch of a product candidate.